GCM
CELL

Glenview Capital Management’s PhenomeX Inc. Common Stock CELL Stock Holding History

Glenview Capital Management’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,816,313
Closed -$3.81M – 56
2023
Q3 		$3.81M Hold
3,816,313
– – 0.09% 47
2023
Q2 		$1.87M Hold
3,816,313
– – 0.04% 44
2023
Q1 		$4.43M Buy
3,816,313
+1,205,636
+46% +$2.2M 0.1% 49
2022
Q4 		$7M Buy
2,610,677
+285,110
+12% +$752K 0.16% 49
2022
Q3 		$6.65M Hold
2,325,567
– – 0.17% 47
2022
Q2 		$11.6M Buy
2,325,567
+1,132,235
+95% +$5.93M 0.29% 42
2022
Q1 		$8.48M Buy
+1,193,332
New +$9.87M 0.17% 51

Glenview Capital Management's CELL Position: Q4 2023 in Review

Glenview Capital Management sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 3,816,313 shares — an estimated $3.81M sold.

Glenview Capital Management first reported a position in CELL in Q1 2022 and held it in 7 quarters. The position peaked at $11.6M in Q2 2022. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.

  • Glenview Capital Management reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Glenview Capital Management sold 3,816,313 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $3.81M.
  • Glenview Capital Management first reported a position in PhenomeX Inc. Common Stock in Q1 2022 and held it in 7 quarters.
  • Glenview Capital Management's PhenomeX Inc. Common Stock position peaked at $11.6M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.

Based on Glenview Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.